


**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in this application:

**Listing of Claims:**

- 1) (Original) A composition comprising one or more salts of tiotropium 1 and one or more pharmacologically acceptable salts of a compound of formula 2'



wherein

- R<sup>1</sup> and R<sup>2</sup> which may be identical or different denote hydrogen or C<sub>1</sub>-C<sub>4</sub>-alkyl;  
R<sup>3</sup> and R<sup>4</sup> which may be identical or different denote hydrogen, C<sub>1</sub>-C<sub>4</sub>-alkyl, -O-C<sub>1</sub>-C<sub>4</sub>-alkyl, -C<sub>1</sub>-C<sub>4</sub>-alkylene-O-C<sub>1</sub>-C<sub>4</sub>-alkyl or  
R<sup>3</sup> and R<sup>4</sup> together denote one of the bridging groups  
-C<sub>1</sub>-C<sub>4</sub>-alkylene- or -O-C<sub>1</sub>-C<sub>4</sub>-alkylene-O-; together with a pharmaceutically acceptable carrier.

- 2) (Original) The composition according to claim 1 wherein the one or more salts of tiotropium 1 is in the form of the chloride, bromide, iodide, methanesulphonate, paratoluene sulphonate or methyl sulphate.

- 3) (Original) The composition according to claim 1 wherein, for the compound of formula 2',

- R<sup>1</sup> and R<sup>2</sup> which may be identical or different denote hydrogen, methyl or ethyl;  
R<sup>3</sup> and R<sup>4</sup> which may be identical or different denote hydrogen, methyl, ethyl, propyl, butyl, methoxy, ethoxy, methoxymethyl, or methoxyethyl, or  
R<sup>3</sup> and R<sup>4</sup> together denote one of the bridging groups

propylene, butylene, -O-ethylene-O- or -O-propylene-O-.

- 4) (Original) The composition according to claim 1 wherein the one or more salts of tiotropium 1 and the one or more pharmacologically acceptable salts of compound 2' are either present together in a single preparation or are contained in two separate preparations.
- 5) (Currently amended) The composition according to claim 4 wherein the weight ratios of 1 to 2' are in the range from 1:300 to 30:1.
- 6) (Currently amended) The composition according to claim 4 wherein a single application corresponds to a dosage of the combination of ~~active substances~~ compounds 1 and 2' of 0.01 to 10000 $\mu$ g.
- 7) (Original) The composition according to claim 4 that it is in the form of a formulation suitable for inhalation.
- 8) (Original) The composition according to claim 7 wherein the form is selected from the group consisting of inhalable powders, propellant-containing metering aerosols and propellant-free inhalable solutions or suspensions.
- 9) (Original) The composition according to claim 8 comprising an inhalable powder which contains 1 and 2 in admixture with suitable physiologically acceptable excipients selected from the group consisting of monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, and mixtures of these excipients.
- 10) (Original) The composition according to claim 9 wherein the excipient has a maximum average particle size of 250 $\mu$ m.
- 11) (Original) The composition according to claim 9 contained in a capsule.
- 12) (Currently amended) The composition according to claim 8 in the form of an inhalable powder consisting essentially of ~~active substances~~ compounds 1 and 2'.

AMENDMENT

U.S. Appln. No. 10/717,868

13) (Currently amended) The composition according to claim 8 in the form of a propellant-containing inhalable aerosol comprising ~~active substances~~ compounds 1 and 2 in dissolved or dispersed form.

14) (Original) The composition according to claim 8 in the form of a propellant-free inhalable solution or suspension comprising water, ethanol or a mixture of water and ethanol as a solvent.

15) (Currently amended) A method for treating inflammatory or obstructive diseases of the respiratory tract comprising the administration to a patient of a therapeutically effective amount of the composition according to claim ~~1~~. 1.